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Abstract: Background
Glucocorticoids and serotonin may mediate the link between maternal environment,
fetal brain development and 'programming' of offspring behaviors. The placenta
regulates fetal exposure to maternal hormonal signals in animal studies, but few data
address this in humans. We measured prospectively maternal depressive symptoms
during pregnancy and mRNAs encoding key gene products determining glucocorticoid
and serotonin function in term human placenta and explored associations with infant
regulatory behaviors.
Methods
Bi-weekly self-ratings of Center for Epidemiological Studies Depression Scale from 12-
13th gestational week onwards and term placental mRNAs of 11beta-hydroxysteroid
dehydrogenase type 2 (HSD2B11), 1 (HSD1B11), glucocorticoid (NR3C1),
mineralocorticoid receptors (NR3C2) and serotonin transporter ( SLC6A4) were
obtained from 54 healthy mothers aged 32.2±5.3 years with singleton pregnancies and
without pregnancy complications. Infant regulatory behaviors (crying, feeding, spitting,
elimination, sleeping and predictability) were mother-rated at 15.6±4.2 days.
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Results
Higher placental mRNA levels of HSD2B11 (0.41 standard deviation [SD] unit increase
per SD unit increase; 95% Confidence Interval, 0.13-0.69, p = 0.005), HSD1B11 (0.30,
0.03-0.57, p = 0.03), NR3C1(0.44, 0.19-0.68, p = 0.001) and SLC6A4 (0.26, 0.00-0.53,
p = 0.05) were associated with more regulatory behavioral challenges of the infant.
Higher placental  NR3C1 mRNA partly mediated the association between maternal
depressive symptoms during pregnancy and infant regulatory behaviors (p <0.05).
Conclusions
Higher placental expression of genes regulating feto-placental glucocorticoid and
serotonin exposure is characteristic of infants with more regulatory behavioral
challenges. Maternal depression acts, at least partly, via altering glucocorticoid action
in the placenta to impact on offspring regulatory behaviors.
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Background 
Glucocorticoids and serotonin may mediate the link between maternal environment, fetal brain 
development and ‘programming’ of offspring behaviors. The placenta regulates fetal exposure to 
maternal hormonal signals in animal studies, but few data address this in humans. We measured 
prospectively maternal depressive symptoms during pregnancy and mRNAs encoding key gene 
products determining glucocorticoid and serotonin function in term human placenta and explored 
associations with infant regulatory behaviors.  
Methods 
Bi-weekly self-ratings of Center for Epidemiological Studies Depression Scale from 12-13th 
gestational week onwards and term placental mRNAs of 11beta-hydroxysteroid dehydrogenase type 
2 (HSD2B11), 1 (HSD1B11), glucocorticoid (NR3C1), mineralocorticoid receptors (NR3C2) and 
serotonin transporter ( SLC6A4) were obtained from 54 healthy mothers aged 32.2±5.3 years with 
singleton pregnancies and without pregnancy complications. Infant regulatory behaviors (crying, 
feeding, spitting, elimination, sleeping and predictability) were mother-rated at 15.6±4.2 days.  
Results  
Higher placental mRNA levels of HSD2B11 (0.41 standard deviation [SD] unit increase per SD unit 
increase; 95% Confidence Interval, 0.13-0.69, p = 0.005), HSD1B11 (0.30, 0.03-0.57, p = 0.03), 
NR3C1(0.44, 0.19-0.68, p = 0.001) and SLC6A4 (0.26, 0.00-0.53, p = 0.05) were associated with 
more regulatory behavioral challenges of the infant. Higher placental  NR3C1 mRNA partly 
mediated the association between maternal depressive symptoms during pregnancy and infant 
regulatory behaviors (p <0.05).  
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Conclusions 
Higher placental expression of genes regulating feto-placental glucocorticoid and serotonin 
exposure is characteristic of infants with more regulatory behavioral challenges. Maternal 
depression acts, at least partly, via altering glucocorticoid action in the placenta to impact on 
offspring regulatory behaviors. 
Key words: mother, placenta, infant, behaviour, pregnancy, mRNA, prospective  
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Introduction 
A wealth of data suggests that exposure to an adverse maternal environment in prenatal life, such as 
obstetric complications, malnutrition, depressed or anxious mood, maternal treatment with synthetic 
glucocorticoids, may exert adverse consequences upon fetal brain development thereby altering 
neurobehavioral trajectories and increasing risk of neuropsychiatric disorders in later life (Cottrell 
and Seckl 2009, Glover 2011, Pesonen et al 2009, Räikkönen et al., 2010; Reynolds et al 2013, 
Roseboom et al 2006, Tuovinen et al 2012) . While the biological mechanisms underpinning this 
developmental plasticity phenomenon, dubbed ‘programming’, still remain elusive, data from 
experimental animal (Benediktsson et al 1997, Cottrell and Seckl 2009, de Vries et al 2007, 
Edwards et al 1993, Holmes et al 2006, Lindsay et al 1996, Lindsay et al 1996, Liu et al 2001, 
Moss et al 2001, Seckl 1998, Seckl and Meaney 2004, Seckl and Holmes 2007, Welberg et al 2000, 
Wyrwoll and Holmes 2012)  and limited emerging human studies (Conradt et al 2013, Moisiadis 
and Matthews 2014, Oberlander et al 2008, O'Donnell et al 2012, Räikkönen et al 2014, Reynolds 
et al 2015)  suggest that fetal overexposure to glucocorticoids may be a key underlying mechanism.  
 
The placenta, which plays a vital role in mediating the maternal hormonal signals to the fetus, 
provides a barrier to fetal exposure to the much higher glucocorticoid levels in the maternal 
circulation (Seckl 1998, Seckl and Meaney 2004, Seckl and Holmes 2007). This is ensured by the 
placental enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) which catalyzes 
metabolism of up to 80-90% of maternal active cortisol to inactive cortisone (Edwards et al 1993) . 
Among the other important placental regulators of feto-placental glucocorticoid overexposure are 
11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which catalyzes regeneration of active 
cortisol from inactive cortisone, and intracellular glucocorticoid (GR) and mineralocorticoid 
receptors (MR), which mediate glucocorticoid actions on gene transcription (Cottrell and Seckl 
2009, Seckl 1998, Seckl and Meaney 2004, Seckl and Holmes 2007). Animal studies have shown 
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that increased feto-placental exposure to active glucocorticoids of maternal origins, alters offspring 
brain anatomy, functioning of the hypothalamic-pituitary-adrenal (HPA) axis, hinders learning and 
memory, and increases anxiety- and depression-like behaviors of the offspring (Holmes et al 2006, 
Welberg et al 2000, Wyrwoll and Holmes 2012) .  
 
Fetal glucocorticoid exposure may also exert effects upon the development and subsequent function 
of the serotonergic nervous system of the offspring (Wyrwoll and Holmes 2012), a key system 
implicated in mood disorders (Ressler and Nemeroff 2000). Glucocorticoid and serotonergic 
systems are known to interact such that glucocorticoids regulate serotonin synthesis, transport, re-
uptake and neuronal receptor expression, while serotonin controls glucocorticoid and 
mineralocorticoid receptor expression in the central nervous system (Wyrwoll and Holmes 2012). 
Recent data in the mouse show that placental deficiency of 11β-HSD2 is associated with increased 
serotonin synthesis and impairment in breakdown of serotonin in the brain of the offspring 
(Wyrwoll and Holmes 2012).  
 
Glucocorticoid (Murphy et al 2006)  and serotonin (Bonnin et al 2011)  systems are both expressed 
in the placenta where interaction might occur and be relevant to exposure of the offspring’s 
developing central nervous system. Yet, we are not aware of previous studies that have tested 
whether alterations in placental expression of key genes determining placental glucocorticoid and 
serotonin function play a role in programming of offspring behavioral outcomes and mediate the 
influence of prenatal maternal environmental adversity on these behavioral outcomes. Therefore, 
we tested if variations in placental mRNAs encoding 11β-HSD2 (HSD11B2), 11β-HSD1 
(HSD11B1), GR (NR3C1), MR (NR3C2) and the serotonin transporter (SLC6A4) were associated 
with differences in regulatory behaviors of the offspring at a mean age of 15.6 days after birth. In 
the tests of mediation we focused on placental mRNA levels of NR3C1 and NR3C2 and on maternal 
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depressive symptoms during pregnancy as the prenatal maternal environmental adversity as we 
have recently shown in this sample that maternal depressive symptoms during pregnancy were 
significantly associated with higher placental mRNA levels of NR3C1 and NR3C2, but were not 
significantly associated with the levels of HSD11B2, HSD11B1  or SLC6A4 (Reynolds et al 2015). 
Consequently, our new analyses reported here extends our previous study by testing if placental 
NR3C1 and NR3C2 mRNAs mediate the influence of maternal depressive symptoms during 
pregnancy on infant regulatory behaviors, providing the other criteria for mediation were also met 
(Hayes 2009), i.e. that placental NR3C1 and NR3C2 mRNAs and maternal depressive symptoms 
during pregnancy were also associated with infant regulatory behaviors.  
 
Methods  
Participants 
The participants were 67 healthy pregnant women enrolled in the Prediction and Prevention of 
Preeclampsia (PREDO) Study as previously described (Räikkönen et al 2014, Reynolds et al 2015, 
Villa et al 2013) . The women did not report using glucocorticoid or antidepressant medication 
during pregnancy, had no obstetric complications and delivered term (37+0 - 41+6 weeks of 
gestation), singleton, healthy infants. Of these, 54 participated in a follow-up study at a mean infant 
age of 15.6 (standard deviation (SD) =4.3) days. Those who did not participate were similar to those 
who did (p > 0.11) except for a higher pre-pregnancy body mass index (mean (standard deviation) 
27.1 (7.8) vs. 22.9 (3.5) kg/m2, p = 0.004), placental weight (640.2 (102.2) vs. 573.8 (83.2) g, p = 
0.02) and shorter length of gestation (275.9 (6.5) vs. 281.2 (8.6) days, p = 0.04) than participants. 
The study protocol was approved by the ethical committees at the Helsinki and Uusimaa Hospital 
district and written informed consent was obtained.  
 
Maternal depressive symptoms  
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Center for Epidemiological Studies Depression Scale (Radloff 1977) for depressive symptoms was 
completed by the mothers bi-weekly during pregnancy from 12-13 gestational weeks onwards up to 
14 times in total. The value at week 12 and mean values across weeks 14-26 and 28-38 were used as 
trimester-specific indices of depressive symptoms during pregnancy (Reynolds et al 2015) .  
 
Placental tissue sampling and gene expression 
Two sets of 9-site biopsies were collected from the decidual side of the placenta a maximum of 90 
minutes after vaginal or caesarean delivery using standard protocols as previously described 
(Räikkönen et al 2014, Reynolds et al 2015) . The biopsies were put in RNA-later and stored at -
20C. Total RNA was extracted from placental tissue sampled from a central site using QIAGEN 
RNeasy mini kits (Qiagen Ltd, West Sussex, UK). The RNA concentration and purity of all 
samples was assessed using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, 
UK) and the integrity of RNA confirmed by separating ribosomal RNA (rRNA) using 
electrophoresis in a 1% agarose/0.5xTBE (45mM Tris-borate, 1mM EDTA) gel with 0.1μl/ml Gel 
Red (Biotium, Hayward, CA, USA) at ~90V for 30 to 50 minutes. cDNA synthesis was carried out 
using the Access RT-PCR system (Promega, Southampton, UK). cDNA was incubated in triplicate 
with gene-specific primers and fluorescent probes either using the Universal Probe Library system 
from Roche Diagnostics Ltd (Burgess Hill, UK) for HSD11B1 (forward primer: 
caatggaagcattgttgtcg, reverse primer: ggcagcaaccattggataag) and  NR3C2 (forward primer: 
tgggaattctgacttacttaacca, reverse primer: aatacaaaaagctgatgcagacc) or pre-designed assays from 
Applied Biosystems ((ABI), CA, USA) for  NR3C1 (Hs00230818_m1),  HSD11B2 
(Hs00388669_m1) and  SLC6A4 (Hs00984349_m1) in RocheLightCycler 480 Probes mastermix. 
PCR cycling and detection of fluorescent signal was carried out using a Roche LightCycler 480. A 
standard curve was constructed for each primer-probe set using a serial dilution of cDNA pooled 
from all samples. Results were corrected to the control gene TATA-binding protein (TBP). 
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Infant regulatory behaviors 
Mothers rated infant regulatory behaviors using the Neonatal Perception Inventory (Broussard and 
Hartner 1971). This inventory captures behaviors relating to infant’s crying, feeding, spitting, 
elimination (bowel movements), sleeping and predictability.  In order to diminish the potential bias 
that may result in too positive or negative perceptions of infant behaviors, the mother was first 
asked to rate concerns relating to regulatory behaviors she would expect an ‘average’ infant to 
display. She was then asked to rate concerns in relation to her own infant’s regulatory behaviors. 
The ratings were made using a five-point scale ranging from no problems to a great amount of 
problems. A difference score between her own and the average infant’s regulatory behaviors (own 
infant – average infant) reflects more regulatory challenges in her own infant’s behavior. A 
principal components analysis revealed one factor (eigenvalue criterion > 1) explaining 40% of the 
total variance, which lends credence to unidimensional structure of the scale and gives support to 
construct validity. Cronbach’s alpha for internal consistency was 0.71 which gives support for the 
scale’s reliability.   
 
Covariates and confounders  
Sample time between placental birth and biopsy (min) was recorded. Mode of delivery (vaginal vs. 
elective/unplanned caesarean), parity (primiparous vs. multiparous), maternal pre-pregnancy body 
mass index (BMI) (kg/m2), maternal age at delivery (yrs), smoking status during pregnancy (yes/no; 
number of cigarettes per day), infant sex (boy vs. girl), gestation length (days) and infant birth 
weight (g) were derived from hospital birth records and the Finnish National Birth Register. 
Alcohol consumption during pregnancy (number of drinks during the past four weeks) and maternal 
level of education (primary, secondary, tertiary) were self-reported. Center for Epidemiological 
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Studies Depression Scale (Radloff 1977) for depressive symptoms was completed by the mothers at 
the infant age of 15.6 days.   
 
Statistical analyses 
Data were analyzed using SPSS Statistics version 22 for IBM. We first used linear regression 
analyses in testing associations between HSD11B2, HSD11B1, NR3C1, NR3C2, SLC6A4 mRNAs in 
term placenta and infant regulatory behaviors at age 15.6 days. We then tested if maternal 
depressive symptoms during pregnancy acted via altering glucocorticoid action in and via the 
placenta to impact on offspring regulatory behaviors by using the Mediate macro for SPSS with 
5000 bootstrapped samples (Hayes and Preacher 2014).  For these analyses gene expression data 
were log transformed to account for non-normality (after transformation skewness index divided by 
standard error < 1.66 for all transformed variables) and thereafter the predictor and outcome 
variables were standardized to the mean of 0 and standard deviation of 1 to facilitate interpretation. 
Hence, unstandardized regression coefficients and 95% confidence intervals (95% CI) or t-statistics 
represent effect sizes, SD unit per SD unit. We present the findings as unadjusted effect sizes and 
effect sizes from linear regression analyses when adjusted simultaneously for sampling time 
between placental birth and biopsy, mode of delivery, parity, maternal pre-pregnancy BMI, 
maternal age at delivery, level of education, smoking status and alcohol consumption during 
pregnancy, gestation length, infant birth weight and sex (Model 1). In linear regression analyses we 
also made adjustments for maternal depressive symptoms measured at the infant age of 15.6 days, 
as maternal depressive symptoms may bias her perceptions (Model 2).  
 
Results   
Table 1 shows clinical characteristics of the sample. Table 2 shows associations between covariates 
and confounders and infant regulatory behaviors. Mothers with a lower level of education and those 
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who reported higher depressive symptoms in the third trimester and at infant age 15.6 days reported 
more infant regulatory behavioral challenges.      
 
Placental mRNA levels and infant regulatory behaviors 
Table 3 shows that higher placental mRNA levels of HSD11B2, HSD11B1, NR3C1, SLC6A4, but 
not NR3C2, were significantly associated with more regulatory behavioral challenges of the infant:  
the increase was 0.41, 0.30, 0.44 and 0.26 SD units per each SD unit increase in the respective 
mRNA level (P-values < 0.05).  Figure 1 displays the regression lines and 95% CIs of the 
significant unadjusted associations and additionally shows that the proportion of variance in infant 
regulatory behaviors accounted for by placental HSD11B2, HSD11B1, NR3C1 and SLC6A4 
mRNAs varied from 8.9 to 19.9 per cent.  
 
Table 3 shows that when we made adjustments for sampling time between placental birth and 
biopsy, mode of delivery, parity, maternal pre-pregnancy BMI, maternal age at delivery, level of 
education, smoking status and alcohol consumption during pregnancy, gestation length, infant birth 
weight and sex (Model 1) the association with HSD11B1  was rendered non-significant; When the 
associations were adjusted for maternal depressive symptoms at  infant age  15.6 days (Model 2) the 
association with SLC6A4 was rendered non-significant (Table 3). 
 
Mediation analyses 
As placental NR3C2 mRNA level was not significantly associated with infant regulatory behaviors 
(Table 3) mediation via NR3C2 mRNA expression was not tested. Similarly, since maternal first 
and second trimester depressive symptoms were not significantly associated with infant regulatory 
behaviors (Table 2) they were not included in the mediation analyses. As maternal depressive 
symptoms during the third pregnancy trimester, placental NR3C1 mRNA level, and infant 
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regulatory behaviors were all significantly inter-related (Reynolds et al., 2015) (Tables 2 and 3), 
and hence the criteria for testing mediation were met (Hayes, 2009, Hayes and Preacher, 2014), we 
pursued in testing if NR3C1 mRNA mediated the effect of maternal depressive symptoms during 
the third pregnancy trimester on infant regulatory behaviors. Indeed, the indirect path via placental 
NR3C1 mRNA was statistically significant (indirect effect = 0.15, 95% CI 0.02-0.38, p < 0.05) 
(Figure 2). Yet, the association between maternal depressive symptoms and infant regulatory 
behaviors was not rendered to zero, but remained ‘marginally’ significant (p = 0.08) (Figure 2). 
This suggested that placental NR3C1 mRNA partly mediated the effect of maternal depressive 
symptoms on infant regulatory behaviors (Figure 2). Figure 2 also shows that the proportion of 
variance in NR3C1 mRNA accounted for by maternal depressive symptoms was 14.4% (p = 0.006) 
and the proportion of variance in infant regulatory behaviors accounted for by maternal depressive 
symptoms and placental NR3C1 mRNA was 24.8% (p = 0.0009). Adjustment for covariates and 
confounders did not alter the significant paths (p-values < 0.05) or mediation (indirect effect = 0.13, 
95% CI 0.01-0.34, p < 0.05 in Model 1; indirect effect = 0.10, 95% CI 0.01-0.30, p < 0.05 in Model 
2). 
 
Discussion  
We show that variation in the mRNA levels of key gene products determining glucocorticoid and 
serotonin function in term human placenta is associated with more regulatory behavioral challenges 
of the infant at 15.6 days. More specifically, higher placental mRNA levels of HSD11B2, 
HSD11B1, NR3C1 and SLC6A4 were associated with infants who subsequently showed greater 
behavioral challenges in crying, sleeping, feeding, spitting and/or elimination.  The findings with 
NR3C1 and HSD11B1 add increased placental sensitivity to glucocorticoids coupled with local 
amplification of glucocorticoid action within the placenta as a mechanism linking increased 
glucocorticoid exposure to adverse offspring outcomes. Yet, the finding of higher placental mRNA 
                                                                                                                   Räikkönen et al.          13  
 
level of  HSD11B2 was contrary to what we expected based on evidence from animal studies where 
fetal glucocorticoid overexposure has been secondary to down-regulation of placental  HSD11B2 
gene expression and activity, and hence inhibition of the function of the placental glucocorticoid 
barrier (Benediktsson et al 1997, Edwards et al 1993, Holmes et al 2006, Lindsay et al 1996, 
Lindsay et al 1996, Seckl 1998, Seckl and Meaney 2004, Seckl and Holmes 2007, Welberg et al 
2000, Wyrwoll and Holmes 2012) . As HSD11B2 excludes glucocorticoids from the 
syncytiotrophoblast we can only speculate that our finding showing that the placental mRNA level 
of HSD11B2 was higher in infants with more behavioral challenges may be an adaptive placental 
response to ameliorate the higher glucocorticoid availability and sensitivity in the placental 
compartment. Moreover the associations with  NR3C1 and  HSD11B2 remained significant when 
we made adjustments for several important factors that we have previously shown to relate to 
placental gene expression (Räikkönen et al 2014, Reynolds et al 2015)  and/or infant regulatory 
behaviors, including mode of delivery, time difference between placental birth and biopsy, maternal 
age at delivery, parity, maternal pre-pregnancy BMI, smoking and alcohol consumption during 
pregnancy, maternal level of education, gestation length, infant birth weight and sex and maternal 
depressive symptoms measured in conjunction with infant behavioral ratings. In the models 
including maternal depressive symptoms at the time of making the infant ratings, HSD11B1 
remained significant while SLC6A4 did not, and in the models including the other covariates 
SLC6A4 remained significant while HSD11B1 did not. 
  
Our study is also the first to show that higher placental NRC31 mRNA level plays a role in the 
process that may partly mediate the effects of higher maternal depressive symptoms during the third 
trimester of pregnancy on more regulatory behavioral challenges of the infant. Statistical mediation 
via NR3C1 mRNA was partial suggesting that other factors may also be involved. These factors 
may include other gene products, such as the corticotropin releasing hormone, or epigenetic 
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modifications involved in the signaling and interactions of glucocorticoids and serotonin between 
the mother, placenta and fetus. Indeed, a recent study demonstrated that higher maternal self-
reported depression during pregnancy and higher placental methylation of the NR3C1 were 
associated with poorer self-regulation, more hypotonia and more lethargy in the infant (Conradt et 
al 2013) . Yet, it remains unknown what the environmental exposures are that underlie the higher 
placental mRNA levels of HSD11B1, HSD11B2 and SLC6A4. While in this study maternal 
depressive symptoms during pregnancy were not associated with mRNA levels of these genes and 
therefore we did not pursue testing them as mediators, one previous study has shown that higher 
maternal anxious but not depressed mood a day before an elective caesarean section was associated 
with lower placental  HSD11B2 mRNA level (O'Donnell et al 2012), and one other study has 
demonstrated that a history of maternal depressed mood during pregnancy, irrespective of the 
maternal antidepressant medication use, was associated with higher placental SLC6A4 mRNA level, 
but not with  HSD11B2 (Ponder et al 2011) . Further studies are clearly warranted that unravel the 
maternal-placental-fetal pathways underpinning individual differences in early infant behaviors. 
  
While we studied healthy term pregnancies, term placentas and healthy infants, our findings may 
have clinical relevance. Infant regulatory behaviors are among the earliest signs of neurobehavioral 
and neuropsychiatric problems in later life. Extensive data, including studies using the Neonatal 
Perception Inventory (the measure as used in our study), suggest that more regulatory behavioral 
challenges of the infant as reported by the mother are associated with later behavioral problems, 
including poorer cognitive functioning (Wolke et al 2009)  and increased risk of externalizing 
behavior problems (Wolke et al 2002)  and attention/deficit hyperactivity disorder (Hemmi et al 
2011, Wolke et al 2002)  in childhood. Extension of our findings into the prevalence of 
neurobehavioral and neuropsychiatric problems in childhood in this sample is subject to ongoing 
studies. 
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We used mother-reports of infant regulatory behavioral challenges. This may introduce a bias that 
results in too positive or negative perceptions of infant behaviors. To overcome any potential bias in 
reporting, the mothers were asked to rate regulatory behaviors she would expect an ‘average’ infant 
to display and then rate her own infant. In addition, we made adjustments for maternal depressive 
symptoms at the time of infant’s assessment and her level of education that were expected to be 
associated with greater behavioral challenges of the infant. The majority of previous studies have, 
however, used mother- or parent-reports of infant regulatory behavioral challenges, as we did. 
Neurologists’ assessments have been used in some studies, but these assessments usually concern 
oral-motor functioning in relation to feeding problems (Schmid et al 2010) . Hence, use of mother-
reports remains a limitation, as long as golden standards do not exist on how to measure regulatory 
behavioral challenges in infancy.     
 
We recognize that we lack data on several elements of the maternal-placental-fetal glucocorticoid 
and serotonin signaling pathway. As we lack data on fetal and intra-placental glucocorticoid and 
serotonin levels, we cannot determine the degree of maternal glucocorticoids and serotonin 
transmitted via the placenta to the fetus. However, while maternal and fetal cortisol levels are 
highly correlated, a recent study has demonstrated that during prenatal life, most fetal serotonin is 
of placental and fetal, not of maternal origins (Bonnin et al 2011) . We also have no information of 
any cell-specificity of actions and changes in the placenta itself, though the full thickness placental 
biopsies will principally reflect fetal characteristics. We only measured mRNA levels of the key 
genes of interest and lack data on levels of their respective protein levels. Further studies are needed 
to determine the mechanisms of altered gene expression, such as methylation of promoter and 
transcription factor binding sites and other epigenetic mechanisms, and whether these are 
modifiable, as are studies that focus on functional end products of the key genes of interest.  Other 
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study limitations relate to external validity of the findings. As the studied sample comprised healthy 
term pregnancies, healthy babies and very few mothers reported depressive symptoms that were 
above the clinical cutoff of the CES-D scale, our findings may not generalize to samples with 
greater variation in adversity.  
 
In conclusion, our findings suggest that higher placental expression of key genes determining 
glucocorticoid and serotonin function in term human placenta and regulating feto-placental 
glucocorticoid and serotonin exposure is characteristic of infants with more regulatory behavioral 
challenges, particularly challenges relating to crying, sleeping, feeding, spitting and elimination 
behaviors. Our findings also suggest that higher placental mRNA levels of the NR3C1 plays a role 
in the process that may partly mediate the effects of maternal depressive symptoms during the third 
trimester of pregnancy on infant regulatory behavioral challenges. Our findings add placental 
glucocorticoid and serotonergic function as novel processes that may underpin developmental 
programming of early infant behaviors. 
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Figure legends 
Figure 1. Unadjusted associations between mRNA levels of 11beta-hydroxysteroid dehydrogenase 
type 2 (HSD11B2; Panel A), 11beta-hydroxysteroid dehydrogenase type 1 (HSD11B1; Panel B), 
glucocorticoid receptor (NR3C1; Panel C) and serotonin transporter (SLC6A4; Panel D) in term 
placenta and infant regulatory behavioral challenges. The lines represent unadjusted unstandardized 
regression coefficients and 95% Confidence Intervals, and R2 refers to the proportion of variance in 
infant regulatory behaviors accounted for by the placental mRNA levels. 
 
Figure 2. Mediation analyses results showing that maternal depressive symptoms during the third 
trimester of pregnancy partly act via altering expression of glucocorticoid receptor (NR3C1) mRNA 
levels in term placenta to impact on infant regulatory behaviors. Numbers represent unadjusted 
unstandardized coefficients, 95% Confidence Intervals, P-values, and R2 refers to the proportion of 
variance in infant regulatory behaviors accounted for by the placental mRNA levels of NR3C1 and 
maternal depressive symptoms, and in placental mRNA levels of NR3C1 by maternal depressive 
symptoms. 
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Table 1. Characteristics of the sample (N=54). 
 M (SD) / N (%) 
Pregnancy and perinatal period:  
mRNA level in term placenta1  
  HSD11B22      0.70 (1.09) 
  HSD11B13 
  NR3C14 
  NR3C25 
  SLC6A46 
0.74 (1.17) 
0.83 (1.23) 
0.80 (2.54) 
0.65 (0.90) 
Delivery mode, N (%)  
  Vaginal 41 (75.9) 
  Elective section 5 (9.3) 
  Unplanned section 8 (14.8) 
Time interval from placental birth to biopsy (min) 48.2 (21.6) 
Weight of placenta (g) 573.8 (83.2) 
Parity, primiparous, N (%) 21 (38.9) 
Maternal age at delivery (yrs) 32.7 (5.2) 
Maternal pre-pregnancy body mass index (kg/m2) 22.9 (3.5) 
Maternal education, tertiary (> 12 years), N (%)   34 (63.0) 
Maternal smoking during pregnancy, N (%)  
  Never smoker 49 (90.7) 
  Quit first trimester 2 (3.7) 
  Smoked throughout7 3 (5.6) 
Maternal alcohol consumption during pregnancy, yes 
(0.5 – 4 drinks the past 4 weeks), N (%)8 
9 (16.7) 
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  Maternal Center of Epidemiological Studies 
  Depression Scale score (Range 0-60) 
 
     First trimester 9.1 (5.3) 
     Second trimester 8.9 (4.7) 
     Third trimester 9.7 (5.3) 
  Maternal Center of Epidemiological Studies 
Depression Scale score ≥ 16, yes, N (%) 
 
     First trimester 8 (15.1) 
     Second trimester 6 (11.1) 
     Third trimester 7 (13.0) 
Gestation length (days) 283.1 (8.4) 
Birth weight (g) 3605 (422) 
Birth length (cm) 51.0 (2.0) 
Ponderal index at birth (kg/m3) 27.7 (2.3) 
Follow-up after birth:  
Infant age (days) 15.6 (4.3) 
  Maternal Center of Epidemiological Studies 
  Depression Scale score (Range 0-60) 
9.2 (7.2) 
  Maternal Center of Epidemiological Studies 
  Depression Scale score ≥ 16, yes, N (%) 
10 (19.6) 
Infant regulatory behaviors9  
    Average infant (Range 1-30) 18.0 (1.8) 
    Own infant (Range 1-30) 19.7 (3.0) 
    Difference score (Own infant – Average infant)   -1.8 (3.3) 
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Note. 1mRNA values are median (interquartile range); 2HSD11B2 refers to 11beta-hydroxysteroid 
dehydrogenase type 2; 3HSD11B1 refers to 11beta-hydroxysteroid dehydrogenase type 1;4 NR3C1 
refers to glucocorticoid receptor, 5NR3C2 refers to mineralocorticoid receptor: 6 SLC6A4 refers to 
serotonin transporter; 7 < 10 cigarettes per day, n = 1; < 10 cigarettes per week or less often, n = 2; 8 
One drink refers to 33 cl of beer or cider (3.5-4.7% vol alcohol), 12 cl of mild  
wine (7-16% vol alcohol), 8 cl of strong wine (15-22% vol), 4 cl of liquor (>22% vol);  
9 Higher values indicate more regulatory behavioral challenges 
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Table 2. Association between covariates and confounders and infant 
regulatory behaviors. 
 
 
 
 
Covariates and confounders: 
More regulatory behavioral 
challenges of the infant 
Effect size in  
SD units1 
 (95% CI) 
 
 
P 
Vaginal delivery vs.   
   Elective section -0.08 (-1.05-0.89) 0.87 
   Unplanned section -0.12 (-0.91-0.67) 0.77 
Time interval between birth and placental 
sampling  
-0.19 (-0.46-0.08) 0.16 
Weight of placenta  0.11 (-0.19-0.41) 0.45 
Primiparous vs. multiparous 0.13 (-0.44-0.69) 0.66 
Maternal age at delivery  0.02 (-0.27-0.30) 0.90 
Maternal primary/secondary vs. tertiary 
education  
-0.87 (-1.38- -0.35) 0.001 
Maternal pre-pregnancy body mass index  -0.13 (-0.51-0.26) 0.52 
Never smoker vs.   
 Quit first trimester -0.38 (-1.85-1.09) 0.61 
Smoked throughout -0.07 (-1.29-1.14) 0.91 
No alcohol consumption vs. yes (0.5-4 drinks 
during past 4 weeks)2 
-0.47 (-1.21-0.25) 0.19 
Infant sex (boy vs. girl) -0.30 (-0.85-0.28) 0.28 
Gestation length (SD units) 0.08 (-0.20-0.35) 0.59 
Birth weight (SD units by sex) 0.01 (-0.26-0.28) 0.94 
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  Maternal Center of Epidemiological 
  Studies Depression Scale score  
  
     First trimester 0.18 (-0.10-0.45) 0.20 
     Second trimester 0.20 (-0.09-0.48) 0.18 
     Third trimester 0.37 (0.09-0.64) 0.01 
        At infant age of 15 days 0.27 (0.01-0.52) 0.04 
Note. 1 SD units, Standard deviation units; 95% CI, 95% Confidence Interval,  
2 One drink of alcohol refers to 33 cl of beer or cider (3.5-4.7% vol alcohol),  
12 cl of mild wine (7-16% vol alcohol), 8 cl of strong wine (15-22% vol), 4 cl of  
liquor (>22% vol). 
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Table 3. Associations between mRNA levels of 11beta-hydroxysteroid dehydrogenase type 2 
(HSD11B2), 11beta-hydroxysteroid dehydrogenase type 1 (HSD11B1), glucocorticoid receptor 
(NR3C1), mineralocorticoid receptor (NR3C2) and serotonin transporter (SLC6A4) in term 
placenta with infant regulatory behaviors. 
 
 
 
mRNA level in 
term placenta: 
More regulatory behavioral challenges of the infant 
Unadjusted 
Effect size in 
SD units1 
 (95% CI) 2 
 
 
 
P 
Model 13 
Effect size in 
SD units1 
 (95% CI) 2 
 
 
 
P 
Model 24 
Effect size in 
SD units1 
 (95% CI) 2 
 
 
 
P 
 HSD11B2 0.41 
(0.13-0.69) 
0.005 0.30 
(0.01-0.58) 
0.04 0.31  
(0.03-0.58) 
0.03 
 HSD11B1 0.30 
(0.03-0.57) 
0.03 0.20 
(-0.10-0.50) 
0.20 0.25 
(0.14-0.61) 
0.002 
 NR3C1 0.44 
(0.19-0.68) 
0.001 0.44 
(0.17-0.71) 
0.002 0.27 
(0.01-0.54) 
0.045 
 NR3C2 0.14 
(-0.16-0.44) 
0.34 0.22 
(-0.09-0.52) 
0.16 0.03  
(-0.24-0.30) 
0.81 
 SLC6A4 0.26 
(0.00-0.53) 
0.047 0.30 
(0.01-0.58) 
0.04 0.23 
(-0.06-0.48) 
0.13 
Note. 1 SD units, Standard deviation units: 2 95% CI, 95% Confidence Interval; 3 Model 1 refers to 
adjustments made for mode of delivery, time difference between placental birth and biopsy, maternal 
age at delivery, maternal education, parity, maternal pre-pregnancy body mass index, smoking and 
alcohol consumption during pregnancy, gestation length, birth weight by sex and infant sex; 4 Model 
2 refers to additional adjustments made for maternal depressive symptoms (Center of 
Epidemiological Studies Depression Scale score) at infant age of 15.6 days.  
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RE: Ref. Ms. No. PSM-D-15-00153 
 
Dear Editor Professor Carmine M. Pariante 
 
Many thanks for your interest in our manuscript that has been re-titled according to suggestions of 
reviewer #1 “Maternal depressive symptoms during pregnancy, placental  expression of genes 
regulating glucocorticoid and serotonin function and infant regulatory behaviors” and for giving 
us the opportunity to revise this. We detail below how we have addressed the concerns by the reviewer.  
 
We believe that our paper has improved considerably and hope that this version of the manuscript is now 
acceptable for publication in Psychological Medicine. 
 
We are looking forwards to hearing your response. 
 
Sincerely, 
 
Katri Räikkönen PhD 
Academy professor 
  
Response to Reviewers
 
Reviewers' and editor's comments: 
 
PLEASE NOTE:  Figures, which should be uploaded as a separate file, should be produced using size 
8 point Arial font for the legend.   Any wording within a figure should ideally be in Arial - 8 point 
size is standard, but this may vary depending on space limitations within individual figures.   
 
RESPONSE: All text and numbers in Figure 1 and 2 are in Arial 8. 
 
Comments by Reviewer #1 
 
Reviewer #1: The focus of this study is to assess the expression of genes regulating glucocorticoid 
and serotonin function in placenta and to determine the association gene expression with 
maternal depressed mood during pregnancy and mother-rated infant behaviour (crying, feeding, 
spitting, elimination, sleeping) at 15.6 days of age. The data on the association of placental gene 
and maternal depressed mood during pregnancy has been published. The study subjects were 
women enrolled in the Prediction and Prevention of Preeclampsia (PREDO) study (n=54 women 
participated in the current study). This is a well written study assessing a well-desinged cohort. 
However, there are serious concerns regarding the over interpretation of the data provided in this 
manuscript. 
 
1. The title should reflect the proper title of genes that were assessed for expression. 
For example, NR3C1 for glucocorticoid receptor and SLC6A4 for serotonin transporter. 
Glucocorticoid and serotonin mRNA levels were not quantified. Alternatively it could not be so 
specific (as in the abstract) and include for example, as statement such as: expression of genes 
regulating serotonin and glucocorticoid function were determined. 
 
RESPONSE: We thank the reviewer for this comment and have changed the title as suggested as 
being less specific. Our paper is now entitled “Maternal depressive symptoms during pregnancy, 
placental expression of genes regulating glucocorticoid and serotonin function and infant 
regulatory behaviors” Please see p 1. 
 
2. Including further experiments, such as protein expression of the relevant genes, etc, 
would strengthen the study. It is unclear what the biological relevance is of the associations 
between gene expression (mRNA) and infant regulatory behaviour.  
 
RESPONSE:  We agree with the reviewer that further experiments that would include 
measurement of functional end products of the key genes of interest would strengthen the study. 
Unfortunately we do not have these data available and therefore cannot include the suggested 
protein expression data in the manuscript. We have added lack of these data in the discussion as a 
study limitation and state that “We only measured mRNA levels of the key genes of interest and 
lack data on levels of their respective protein levels. Further studies are needed to determine the 
mechanisms of altered gene expression, such as methylation of promoter and transcription factor 
binding sites and other epigenetic mechanisms, and whether these are modifiable as are studies 
that focus on functional end products of the key genes of interest.”  Please see p 15. 
 
3. It would be useful to include some analysis in the children eg cord blood. 
 
RESPONSE: This would indeed be interesting. The sample size is however small and this would add 
a level of complexity to the findings reported here. Apart of phenotypic data, further studies are 
clearly warranted that include analyses of biological samples of the children as well. In the 
discussion we have stated that “We recognize that we lack data on several elements of the 
maternal-placental-fetal glucocorticoid and serotonin signaling pathway.” Please see p 15. 
 
4. Given the numerous studies assessing methylation of the genes the study would be 
strengthened by including analyses of gene promoter methylation and assessing the association 
with gene expression. 
 
RESPONSE: This would be interesting too. We have discussed lack of these data as a study 
limitation. “Further studies are needed to determine the mechanisms of altered gene expression, 
such as methylation of promoter and transcription factor binding sites and other epigenetic 
mechanisms, and whether these are modifiable, as are studies that focus on functional end 
products of the key genes of interest. “ Please see p 15. 
 
5. It would be useful to see what the RNA data looks like rather than just providing the 
effect size in the regression models. 
 
RESPONSE: We have now reported median values and interquartile ranges, rather than mean 
values and standard deviations because of the skewed distributions, of the mRNA levels of the key 
genes of interest in Table 1. For analyses these variables were log-transformed and we now report 
in the statistical analysis section that this transformation was successful as requested by reviewer 
#3. Please see Table 1. 
 
6. Please use proper gene names for the RNA data. Without this, it is difficult to gage 
the biological relevance of the findings. 
 
RESPONSE: As suggested by the reviewer, we have used proper gene names throughout the 
manuscript.  
 
7. The scatter plots are difficult to read. Are adjusted or unadjusted values plotted? 
 
RESPONSE: We are plotting unadjusted values and have now clarified this in the results section as 
well as in the figure legend.  We have clarified this in the figure legends and in the results section. 
Please see p 11, 12 and 22. 
 
8. Discussion. Data must not be over interpreted. Only mRNA levels were assessed, 
which really does not tell anything regarding protein or activity. For example, a statement such as 
1st sentence, paragraph 2, page 13, … `higher placental GR mRNA level may mediate the effects of 
higher maternal depressive symptoms during third trimester of pregnancy on more regulatory 
behavioural challenges of the infant.' It's unclear how biologically NR3C1 mRNA expression in 
placenta could affect infant behaviour at 15 days of age without additional experiments. 
 
RESPONSE: We agree with the reviewer and have now stated that “Our study is also the first to 
show that higher placental NRC31 mRNA level plays a role in the process that may mediate the 
effects of higher maternal depressive symptoms during the third trimester of pregnancy on more 
regulatory behavioral challenges of the infant.” Please see p 13 and 16. 
 
Comments by Reviewer #2 
 
Reviewer #2: RE: Manuscript number PSM-D-15-00153, "Maternal depressive symptoms during 
pregnancy, placental glucocorticoid and serotonin mRNA levels and infant regulatory behaviors." 
The premise of this manuscript was to identify associations between prenatal exposure to 
maternal depressive symptoms, mRNA levels, indicating gene expression, of genes involved in the 
newborn response to stress, and newborn regulatory behaviors. This is a very exciting and 
generally methodologically sound study. Most of the epigenetic literature in humans testing 
prenatal programming hypotheses are related to prenatal exposures and DNA methylation, but 
very few look at gene expression or relate gene expression to infant behavioral outcomes. While 
there are some limitations, I think they can be addressed or at the very least noted in the 
discussion. If this paper gets published (and I think it should) I think it will have a very high impact.  
 
1. Introduction: I think the significance and innovation of this study would be 
strengthened with a discussion about how very few (if any) studies relate placental gene 
expression to functional behavioral outcomes in infancy. Discuss why such studies are important 
(e.g., tests of prenatal programming hypotheses need to demonstrate that prenatal experiences 
relate to behavioral outcomes). 
 
RESPONSE: We thank the reviewer for this suggestion. We have modified the text in the 
introduction to point out this novel aspect of our study. Please see p 6 and 7. 
 
2. These ideas are not clear, "We have previously shown in this sample that maternal 
depressive symptoms during pregnancy were significantly associated with higher placental mRNA 
levels of GR and MR, but were not significantly associated with the levels of 11β-HSD2, 11β-HSD1 
and SERT (Reynolds et al 2015). Consequently, placental GR and MR mRNAs could be tested as 
potential mediators providing the other criteria for mediation were met (Hayes 2009): namely, 
that placental GR and MR mRNAs and maternal depressive symptoms during pregnancy were also 
associated with infant regulatory behaviors. Hence, our secondary objective was to examine if 
maternal depressive symptoms acted via altering glucocorticoid action in and via the placenta to 
impact on infant regulatory behaviors." I think the authors are saying there were no main effects 
of depressive symptoms on mRNA 11β-HSD2, 11β-HSD1 and SERT but that does not rule out that 
these genes may serve as mediators of infant behavioral outcomes. Thus, the authors include 
these genes in their analysis since there is evidence that they may mediate the effect of depressive 
symptom exposure on newborn outcomes. If I am misunderstanding, though, please clarify. 
 
RESPONSE: We have edited this part of the introduction and hope that the rationale for including 
NR3C1 and NR3C2 in the mediation analyses is now made clearer. Please see p 6 and 7. 
 
3. Please include assay design information for GR, 11β-HSD2 and SERT (this could be in 
an appendix or in online supplementary material). 
 
RESPONSE: These were pre-designed assays but the reference number has been added. Please see 
p 8. 
 
 
4. I think the biggest limitation of this study is that the measure of infant regulatory 
behaviors is not particularly strong. It is maternal report, though I appreciate that the authors 
tried to limit maternal bias. For instance, it is well known that mothers with depression rate their 
infant as temperamentally more difficult. Including an objective measure of newborn 
neurobehavior, such as the NNNS, would increase the reliability and validity of this construct. 
Given that this field is in it's infancy, however, I do not think their measure of infant regulatory 
behavior is woefully inadequate, and the authors note the limitations of their instrument in the 
discussion.   
 
RESPONSE: Unfortunately we did not include the NNNS in our study protocol. We have, as the 
reviewer points out, discussed the limitations related to the measure of infant regulatory 
behaviors. 
 
5. It would be helpful if the authors included their rational behind assessing prenatal 
maternal depression during the first, second, and third trimesters. What were the correlations 
between CESD scores during each trimester? Previous work shows that maternal anxiety during 
2nd trimester (but not 3rd) is related to child behavioral outcomes. Why would only 3rd trimester 
depression be significantly associated with newborn behavior? 
 
RESPONSE: We have reported these correlations in our recently published paper by Reynolds RM, 
Pesonen A-, O’Reilly J, Tuovinen S, Lahti M, Kajantie E, Laivuori H, Villa P, Hämäläinen E, Seckl JR, 
Räikkönen K (2015). Maternal depressive symptoms throughout pregnancy are associated with 
increased placental glucocorticoid sensitivity. Psychological Medicine. Advance Online Publication. 
DOI: http://dx.doi.org/10.1017/S003329171400316X). 
 
In the paper cited above we have reported that the mean CES-D scores at each time point were 
significantly correlated: r= 0.66, 0.67 and 0.83 (all p-values <0.001) between first trimester value 
and second trimester mean value, first trimester value and third trimester mean value, and second 
and third trimester mean values, respectively.  
 
In the paper cited above we have also discussed why depression at different time points during 
gestation may have different effects: It is recognized that there are critical windows during 
gestation when the developing fetus may be particularly vulnerable to in utero exposures 
(Räikkönen et al., 2012). For example, the third trimester has been shown to be a vulnerable time 
when maternal mental state and cortisol levels are linked to later offspring outcome (Yehuda et 
al., 2005). These findings suggest that maternal mood earlier in pregnancy can also influence fetal 
glucocorticoid exposure and outcome.  
 
6. Is the regulatory measure comprised of different scales? Could the authors use factor 
analysis to determine if different scales emerge? Otherwise, could the authors justify their choice 
of examining whether certain genes are related to specific regulatory behaviors? Do the authors 
have hypotheses regarding why the expression of certain genes should be related to, for example, 
crying but not spitting up? I don't think this section of the manuscript is necessary unless the 
authors have a clear theoretical rational. 
 
RESPONSE: We have included the results of a principal components analysis to the revised version 
of the manuscript. This analysis supports unidimensionality of the scale. Please see p 9.  Further, 
as the reviewer suggests we have deleted the findings in relation to ‘different’ regulatory 
behaviors from the results section as the scale is clearly unidimensional. 
 
7. Could the authors please clarify heading, "Placental GR mRNA levels as a mediator." 
A mediator of what? 
 
RESPONSE: We have edited the heading and in the revised version it is ‘Mediation analyses’. 
Please see p 11.  
 
8. Another limitation is that most women seemed to have lower depressive symptoms. 
How many fell in clinical range (CESD of 16 or above?) Again, this is not justification for not 
accepting the paper, but a limitation that should be addressed, since most of the epigenetic 
literature on maternal depression includes relatively well-off, "low risk" samples. 
 
RESPONSE: In Table 1 we have reported the number of women who scored CES-D of 16 or above 
at each trimester and have noted that the health of the sample may limit generalizability from 
these findings in the discussion. Please see Table 1 and p 16. 
 
Comments by Reviewer #3 
 
Reviewer #3: Comments for Author (s) 
Title: Maternal depressive symptoms during pregnancy, placental glucocorticoid and serotonin 
mRNA levels and infant regulatory behaviors 
MS: PSM-D-00153 
 
This paper tests mediation of mRNA levels in the association between maternal depressive 
symptoms during pregnancy and infant regulatory behaviors.  mRNA levels in placenta for 11B-
HSD2, 11B-HSD1,  GR, and SERT were associated with greater "regulatory behavioral challenges" 
during infancy in models that adjusted for multiple variables. GR mRNA mediated the association 
between depressive symptoms and regulatory behaviors. Overall, this is an interesting paper and 
likely one of the few examples linking mRNA from placental tissue to maternal ratings of infant 
behavior. There are some concerns, outlined below, that deserve further clarification.  
 
1) It's not completely clear how the 2015 paper and the current paper diverge in their 
presentation. From my reading, depressive symptoms and their relation to mRNA levels was the 
focus of the first paper whereas this second is focused on 1) depressive symptoms and mRNA 
levels and their relation to child outcomes, and 2) potential mediation of mRNA in the pathway 
from maternal depression to child outcomes. The set-up for this paper and how it builds from or is 
different from the previous paper needs to be made clearer in the last paragraph of the 
introduction. The description that is currently there needs to be more explicit.   
 
RESPONSE: We have edited the last paragraph of the introduction to be more explicit on how this 
work differs from what we previously reported. We hope that the edited text is clearer. Please see 
p 6 and 7. 
 
2) Since child regulatory behaviors is a critical piece of this paper, it is important to 
describe the validity of this measure in the methods section. Some of this information comes later 
in the discussion, but should be also in the methods section. More information in the methods 
section is needed to confirm for the reader that this measure of regulatory behaviors is indeed 
meaningful. Most of the items seem to reflect normal behavior for a 1 year old infant.  The alpha 
level is moderate. Further, the method for assessment (a difference score), while interesting, may 
or may not be valid.     
 
RESPONSE: We have included results of the principal components analyses to support the validity 
of this scale. We have however not presented data on criterion validity in the methods section and 
then repeated these data in the discussion, as we would like to present the reader a more 
thorough discussion related to different aspects of the measure including its’ limitations.  Please 
see p 9. 
 
3) The data were transformed, but the results of this transformation were not reported. 
Was the transformation effective?  Are the regression residuals normally distributed after 
transformation? 
 
RESPONSE: We used log-transformation for the variables and then standardized the variables to 
mean of 0 and standard deviation of 1. We have included a sentence in the statistical analyses 
indicating that the log-transformation was successful. Please see p 10. 
 
4) The sample size is fairly small and there are several covariates in the analysis. Power 
to detect associations, as well as mediation effects, may be compromised. Post-hoc power analysis 
could help in this respect. 
 
RESPONSE: We agree that the sample size is small. However, if we did not detect significant 
associations, then we think that post hoc power analysis would be in place, though post hoc 
power calculations are not recommended in general (because actual relative estimate and its 
variance are being ignored, which by the time of analysis are already known) (e.g. Smith and Bates 
(1992) Confidence limit analyses should replace power calculations in the interpretation of 
epidemiologic studies. Epidemiology 3 449-450). Since we detected significant associations, our 
sample provides sufficient power to detect at least robust significant associations as reported in 
Tables and Figures.  Also, inspection of the confidence intervals supports detection of robust 
associations (if sample size is too small, this is reflected in wide CIs, Bates and Smith (1992)).  
 
5) In general, it would be useful to interpret the effect sizes for the reader. Most of the 
effects are fairly small. The proportion of the mediated effect could be calculated and reported. 
Specifically, what percent of variance is accounted for by the mediated effect? Also, in the 
mediation analyses it is not clear if maternal depression at the time of her rating of her child was 
in the model. This should be clarified. 
 
RESPONSE: This is a good point. We have included the proportion of variance accounted for in 
mRNA of NR3C1 by maternal depressive symptoms and in regulatory behaviors by NR3C1 and 
depressive symptoms. Please see Figure 2 and text reporting the mediation analyses on p 12. 
 
6) Given the small sample effects, what else besides maternal depression drives mRNA 
levels of these genes? Could be useful in the discussion to comment on this and why this was not 
analyzed in the models.   
 
RESPONSE: We have included a number of covariates and confounders that may either drive 
mRNA levels or ratings of infant regulatory behaviors. We have also discussed the findings in the 
context of previous research. We have however left out discussion of common pregnancy 
disorders, pre-eclampsia and gestational diabetes, as women in our sample did not suffer from 
these complications. 
 
7) In general, it could be made clearer what is actually being measured from placental 
expression of key genes. Is this a mix of maternal and infant blood - so are the expression levels 
characteristic of mothers or offspring, or does it matter? 
 
RESPONSE:  We acknowledge that a limitation of the study is that we used full thickness placental 
biopsies and so while predominantly reflecting fetal characteristics there may be mixture of 
maternal and fetal tissue. We have included this limitation in the discussion. Please see p 15. 
 
